F Pasini
Overview
Explore the profile of F Pasini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campos-Fernandez D, Montes A, Thonon V, Sueiras M, Rodrigo-Gisbert M, Pasini F, et al.
Epilepsy Behav
. 2024 May;
156:109841.
PMID: 38768551
Introduction: Seizures are a common complication of subarachnoid hemorrhage (SAH) in both acute and late stages: 10-20 % acute symptomatic seizures, 12-25 % epilepsy rate at five years. Our aim...
2.
Danese E, Minicozzi A, Benati M, Paviati E, Lima-Oliveira G, Gusella M, et al.
Sci Rep
. 2017 Aug;
7(1):8413.
PMID: 28827728
MicroRNAs (miRNAs) hold great promise in cancer research. The use of appropriate reference miRNAs for normalization of qPCR data is crucial for accurate expression analysis. We present here analysis and...
3.
Gusella M, Pezzolo E, Modena Y, Barile C, Menon D, Crepaldi G, et al.
Pharmacogenomics J
. 2017 Jun;
18(1):14-22.
PMID: 28607505
The role of genetic molecular markers in neoadjuvant treatment for locally advanced esophageal cancer has been reviewed, focusing strictly on concurrent chemoradiation protocols followed by surgery. Eleven studies evaluated the...
4.
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, et al.
Ann Oncol
. 2017 Mar;
28(12):3110.
PMID: 28327986
No abstract available.
5.
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, et al.
Ann Oncol
. 2016 Aug;
27(11):2074-2081.
PMID: 27573560
Background: Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. A shorter duration of...
6.
Gusella M, Giacopuzzi S, Bertolaso L, Zanoni A, Pezzolo E, Modena Y, et al.
Pharmacogenomics J
. 2016 Mar;
17(3):252-257.
PMID: 26927287
Candidate genes involved in DNA repair, 5-fluorouracil metabolism and drug detoxification were genotyped in 124 patients receiving neoadjuvant chemoradiation treatment for locally advanced esophageal cancer and their predictive role for...
7.
Tabanelli G, Verardo V, Pasini F, Cavina P, Lanciotti R, Caboni M, et al.
J Dairy Sci
. 2015 Nov;
99(1):120-9.
PMID: 26547644
In this study, the survival of the functional yeast Kluyveromyces marxianus B0399 in an industrially produced fermented milk was evaluated. In particular, the yeast viability was assessed throughout the entire...
8.
Rumiato E, Brunello A, Ahcene-Djaballah S, Borgato L, Gusella M, Menon D, et al.
Pharmacogenomics J
. 2015 Oct;
16(6):525-529.
PMID: 26503812
So far, no reliable predictive clinicopathological markers of response to aromatase inhibitors (AIs) have been identified, and little is known regarding the role played by host genetics. To identify constitutive...
9.
Boldrin E, Rumiato E, Fassan M, Rugge M, Cagol M, Marino D, et al.
Pharmacogenomics J
. 2015 Jun;
16(3):266-71.
PMID: 26054330
The occurrence of a second primary esophageal carcinoma (EC) in long-term cancer survivors may represent a late effect of previous radio-chemotherapeutic treatment. To identify the genetic factors that could increase...
10.
Danese E, Minicozzi A, Benati M, Montagnana M, Paviati E, Salvagno G, et al.
Br J Cancer
. 2013 Jul;
109(3):807-13.
PMID: 23839493
Background: Tumour-released DNA in blood represents a promising biomarker for cancer detection. Although epigenetic alterations such as aberrant promoter methylation represent an appealing perspective, the discordance existing between frequencies of...